|
1
|
Bröckelmann PJ, McMullen S, Wilson JB, Mueller K, Goring S, Stamatoullas A, Zagadailov E, Gautam A, Huebner D, Dalal M, Illidge T. Patient and physician preferences for first-line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom. Br J Haematol 2018; 184:202-214. [PMID: 30239982 PMCID: PMC6585631 DOI: 10.1111/bjh.15566] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2018] [Accepted: 07/09/2018] [Indexed: 12/02/2022]
Abstract
First‐line treatments for classical Hodgkin lymphoma (HL) include ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) and BEACOPPescalated (escalated dose bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone). To further improve overall outcomes, positron emission tomography‐driven strategies and ABVD or BEACOPP variants incorporating the antibody‐drug conjugate brentuximab vedotin (BV) or anti‐PD1 antibodies are under investigation in advanced‐stage patients. The present study aimed to elicit preferences for attributes associated with ABVD, BEACOPPescalated and BV‐AVD (BV, adriamycin, vinblastine and dacarbazine) among patients and physicians. Cross‐sectional online discrete choice experiments were administered to HL patients (n = 381) and haematologists/oncologists (n = 357) in France, Germany and the United Kingdom. Included attributes were progression‐free survival (PFS), overall survival (OS), and the risk of neuropathy, lung damage, infertility and hospitalisation due to adverse events. Whereas 5‐year PFS and OS were the most important treatment attributes to patients, the relative importance of each attribute and preference weights for each level varied among physicians according to the description of the hypothetical patient for whom treatment was recommended. PFS and OS most strongly influenced physicians’ recommendations when considering young female patients who did not want children or young male patients. Infertility was more important to physicians’ treatment decision than PFS when considering young women with unknown fertility preferences, whereas hospitalisations due to adverse events played the largest role in treatment decisions for older patients.
Collapse
Affiliation(s)
- Paul J Bröckelmann
- Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany
| | | | | | | | | | | | - Erin Zagadailov
- Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA
| | - Ashish Gautam
- Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA
| | - Dirk Huebner
- Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA
| | - Mehul Dalal
- Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA
| | - Tim Illidge
- Institute of Cancer Sciences, University of Manchester, Christie Hospital, Manchester, UK
| |
Collapse
|
|
3
|
Houot R, Gaulard P, Schreiber R, Mellman I, Lambotte O, Coulie PG, Fest T, Korman A, Levy R, Shipp M, Tarte K, Kohrt H, Marabelle A, Ansell S, Watier H, van Elsas A, Balakumaran A, Arce Vargas F, Quezada SA, Salles G, Olive D. Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop. Oncoimmunology 2016; 5:e1186323. [PMID: 27622041 DOI: 10.1080/2162402x.2016.1186323] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2016] [Revised: 04/26/2016] [Accepted: 04/30/2016] [Indexed: 01/21/2023] Open
Abstract
In November 2015, the CALYM Carnot Institute held a 2-d workshop to discuss the current and future development of immunomodulatory antibodies for the treatment of lymphoma. Highlights from the workshop are presented in this article.
Collapse
Affiliation(s)
- Roch Houot
- Department of Hematology, CHU de Rennes , Rennes, France
| | - Philippe Gaulard
- Department of Pathology, Inserm U955, Université Paris-Est, CHU Henri Mondor , Créteil, France
| | - Robert Schreiber
- Department of Pathology and Immunology, Washington University , St. Louis, MO, USA
| | | | - Olivier Lambotte
- Department of Clinical Immunology and Internal Medicine, Hospital Kremlin Bicêtre, Université Paris-Sud , Orsay, France
| | - Pierre G Coulie
- de Duve Institute, Université Catholique de Louvain , Brussels, Belgium
| | | | | | - Ronald Levy
- Stanford School of Medicine , Stanford, CA, USA
| | | | | | - Holbrook Kohrt
- Department of Medicine, Stanford School of Medicine , Stanford, CA, USA
| | | | - Stephen Ansell
- Division of Hematology , Mayo Clinic, Rochester, MN, USA
| | - Hervé Watier
- CHRU de Tours, Université François-Rabelais and CNRS, UMR7292 , Tours, France
| | | | | | | | | | - Gilles Salles
- Department of Hematology, Université Claude Bernard, Hospices Civils de Lyon , INSERM 1052 , Lyon, France
| | - Daniel Olive
- Inserm UMR 1068, Institut Paoli Calmettes, Aix Marseille Université , Marseille, France
| |
Collapse
|